FEDERAL COURT OF AUSTRALIA
Sanofi-Aventis Deutschland GmbH v Alphapharm Pty Ltd [2019] FCAFC 28
Appeal from: Sanofi-Aventis Deutschland GmbH v Alphapharm Pty Ltd
(No 3) [2018] FCA 2060File number: NSD 2398 of 2018 Judges: JAGOT, YATES AND MOSHINSKY JJ Date of judgment: 22 February 2019 Catchwords: [PRACTICE AND PROCEDURE- patents – interlocutory injunction application – prima facie case
– validity of patents – novelty – balance of convenience- leave to appeal dismissed.
Cases cited: GenRx Pty Ltd v Sanofi-Aventis [2007] FCA 148
House v The King (1936) 55 CLR 499
Interpharma Pty Ltd v Commissioner of Patents [[2008] FCA 1498
Janssen Sciences Ireland UC v Alphapharm Pty Ltd [2017] FCA 1399
Love v Thwaites & Anor (No 4) [2012] VSC 521
Love v Thwaites & Anor [2014] VSCA 56
Samsung Electronics Company Ltd v Apple Inc (2011) 217 FCR 238
Sanofi-Aventis Deutschland GmbH v Alphapharm Pty Ltd (No 3) [2018] FCA 2060
Date of hearing: 8 February 2019 Registry: New South Wales Division: General National Practice Area: Intellectual Property Sub-area: Patents and Associated Statutes Category: Catchwords Number of paragraphs: 54 Counsel for the Applicants: C Dimitriadis SC with A R Lang Solicitor for Applicants: Jones Day Counsel for the Respondent: T D Cordiner QC with J S Cooke Solicitor for the Respondent: MinterEllison ORDERS
NSD 2398 of 2018 BETWEEN: SANOFI- AVENTIS DEUTSCHLAND GMBH & ANOR
ApplicantsAND: ALPHAPHARM PTY LTD
Respondent
JUDGES:
JAGOT, YATES AND MOSHINSKY JJ
DATE OF ORDER:
22 FEBURARY 2019
THE COURT ORDERS THAT:
1.The application for leave to appeal be dismissed.
2.The applicants pay the respondent’s costs of the application as agreed or taxed.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
REASONS FOR JUDGMENT
THE COURT:
This application for leave to appeal concerns the primary judge’s refusal to grant the applicants, Sanofi-Aventis Deutschland GmbH and Sanofi-Aventis Australia Ltd (together, Sanofi), an interlocutory injunction to restrain the respondent, Alphapharm Pty Ltd, from launching its SEMGLEE insulin glargine (rDNA) solution for injection injector pen, referred to as the Semglee product: Sanofi-Aventis Deutschland GmbH v Alphapharm Pty Ltd (No 3) [2018] FCA 2060.
Sanofi contends that the primary judge’s refusal to grant the interlocutory injunction is attended by sufficient doubt to justify the Full Court reconsidering the matter and that, assuming the primary judge’s decision to be wrong, it would suffer substantial injustice. The latter condition of substantial injustice if the decision is wrong is satisfied and, as a result, it was decided that the application for leave to appeal and the appeal should be heard together.
We consider that the application for leave to appeal should be refused. The primary judge’s decision is not attended by sufficient doubt to justify the Full Court reconsidering the application for an interlocutory injunction.
The draft notice of appeal identifies 11 alleged errors, many containing multiple aspects each said to constitute error.
One answer to the…
Keep reading for free
Create a free CaseChat account to read Sanofi-Aventis Deutschland GmbH v Alphapharm Pty Ltd and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2019] FCAFC 28
- Decision Date
CaseChat Overview and Summary
The court was required to determine the validity of Sanofi-Aventis’s patents, specifically whether they were novel and non-obvious, and whether Alphapharm had infringed these patents. Additionally, the court had to consider the balance of convenience to decide if an interlocutory injunction should be granted. The court examined the evidence presented regarding the novelty of the patents and the infringement by Alphapharm, weighing the potential harm to both parties if the injunction was or was not granted.
Sanofi-Aventis argued that their patents were valid and that Alphapharm had infringed them by producing generic versions of the drugs. However, the court found that Sanofi-Aventis had not demonstrated a prima facie case for patent validity or infringement. The court also concluded that the balance of convenience did not favour granting an interlocutory injunction. Consequently, the application for leave to appeal was dismissed. The applicants were ordered to pay the respondent’s costs of the application as agreed or taxed.
Orders
Orders of the court
1. The application for leave to appeal be dismissed.
2. The applicants pay the respondent’s costs of the application as agreed or taxed.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi